Corvel Corp CRVL
We take great care to ensure that the data presented and summarized in this overview for CORVEL CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRVL
View all-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA5.71MShares$621 Million1.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$357 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.86MShares$202 Million0.33% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.55MShares$168 Million0.04% of portfolio
-
Black Rock Inc. New York, NY1.47MShares$160 Million0.01% of portfolio
-
State Street Corp Boston, MA1.11MShares$121 Million0.01% of portfolio
-
Neuberger Berman Group LLC New York, NY846KShares$92 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA775KShares$84.3 Million0.01% of portfolio
-
Boston Trust Walden Corp678KShares$73.7 Million0.56% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD626KShares$68 Million0.01% of portfolio
Latest Institutional Activity in CRVL
Top Purchases
Top Sells
About CRVL
CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.
Insider Transactions at CRVL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
Apr 09
2025
|
Jeffrey J Michael Director |
SELL
Open market or private sale
|
Direct |
16,523
-1.46%
|
$1,916,668
$116.97 P/Share
|
Apr 03
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
471
-1.47%
|
$52,281
$111.12 P/Share
|
Apr 03
2025
|
Brandon O'Brien Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+3.0%
|
$14,500
$29.23 P/Share
|
Apr 01
2025
|
R Judd Jessup Director |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-0.67%
|
$99,101
$113.41 P/Share
|
Apr 01
2025
|
R Judd Jessup Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+6.41%
|
$99,000
$11.05 P/Share
|
Mar 31
2025
|
Jennifer Yoss Vice President of Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
24
+1.14%
|
$2,544
$106.37 P/Share
|
Mar 31
2025
|
Brandon O'Brien Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24
+0.15%
|
$2,544
$106.37 P/Share
|
Mar 31
2025
|
Michael G Combs CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
60
+0.06%
|
$6,360
$106.37 P/Share
|
Mar 31
2025
|
Mark E. Bertels EVP - Risk Management Services |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.23%
|
$636
$106.37 P/Share
|
Mar 14
2025
|
Maxim Shishin Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+24.19%
|
$38,250
$17.56 P/Share
|
Feb 20
2025
|
Jeffrey J Michael Director |
SELL
Open market or private sale
|
Direct |
10,477
-0.6%
|
$1,225,809
$117.3 P/Share
|
Feb 19
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,512
-8.82%
|
$176,904
$117.54 P/Share
|
Feb 18
2025
|
Alan Hoops Director |
SELL
Open market or private sale
|
Indirect |
10,200
-4.05%
|
$1,183,200
$116.39 P/Share
|
Feb 11
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,523
-4.14%
|
$181,237
$119.56 P/Share
|
Feb 07
2025
|
Alan Hoops Director |
SELL
Open market or private sale
|
Indirect |
800
-0.62%
|
$96,800
$121.1 P/Share
|
Feb 07
2025
|
Alan Hoops Director |
SELL
Open market or private sale
|
Direct |
4,000
-16.89%
|
$484,000
$121.29 P/Share
|
Feb 07
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
991
-5.04%
|
$120,902
$122.02 P/Share
|
Feb 06
2025
|
Steven J Hamerslag Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.09%
|
$1,230,000
$123.48 P/Share
|
Feb 06
2025
|
Brandon O'Brien Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
988
-2.41%
|
$120,536
$122.76 P/Share
|
Feb 06
2025
|
Brandon O'Brien Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.62%
|
$29,000
$29.23 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 54.3K shares |
---|---|
Grant, award, or other acquisition | 142 shares |
Payment of exercise price or tax liability | 14.2K shares |
---|---|
Open market or private sale | 186K shares |
Bona fide gift | 78.3K shares |